Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation

Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation

Purpose: Glioblastomas (GBM) are the most common malignant primary brain tumors in adults and have a dismal prognosis. Patients frequently suffer from local tumor recurrences, with limited therapeutic options. Re-irradiation represents a possible intervention, but given the recent 5th edition of the...

Full description

Bibliographic Details
Main Authors:	Felix Ehret, Josy Wolfgang, Luisa Allwohn, Julia Onken, David Wasilewski, Siyer Roohani, Joachim Oertel, Daniel Zips, David Kaul
Format:	Article
Language:	English
Published:	Elsevier 2023-09-01
Series:	Clinical and Translational Radiation Oncology
Subjects:	Glioblastoma Isocitrate Dehydrogenase IDH Re-irradiation Radiotherapy Radiation Necrosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405630823000782

Similar Items

Treating oligodendroglioma – An analysis of a homogeneous 1p/19q-codeleted and isocitrate dehydrogenase-mutant patient cohort
by: Luisa Allwohn, et al.
Published: (2023-07-01)

Characterization of the Isocitrate Dehydrogenase Gene Family and Their Response to Drought Stress in Maize
by: Ningning Wei, et al.
Published: (2023-10-01)

Multiparametric Magnetic Resonance Imaging Correlates of Isocitrate Dehydrogenase Mutation in WHO high-Grade Astrocytomas
by: Arpita Sahu, et al.
Published: (2022-12-01)

Development of a novel glycolysis-related genes signature for isocitrate dehydrogenase 1-associated glioblastoma multiforme
by: Xiaomin Cai, et al.
Published: (2022-10-01)

Stochastic Microsensors Based on Carbon Nanotubes for Molecular Recognition of the Isocitrate Dehydrogenases 1 and 2
by: Raluca-Ioana Stefan-van Staden, et al.
Published: (2022-01-01)

Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms
by: Jacqueline Kessler, et al.
Published: (2019-06-01)

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
by: Felix Neumaier, et al.
Published: (2023-03-01)

Biochemical Characterization of Recombinant Isocitrate Dehydrogenase and Its Putative Role in the Physiology of an Acidophilic Micrarchaeon
by: Dennis Winkler, et al.
Published: (2021-11-01)

Fluorometric determination of isocitrate dehydrogenase (EC 1.1.1.42; 1; NADP+ dependent) in ruminant milk
by: T. Larsen, et al.
Published: (2022-08-01)

<i>IDH</i> Mutations in Glioma: Double-Edged Sword in Clinical Applications?
by: Alisan Kayabolen, et al.
Published: (2021-07-01)

Research Progress and Prospects of Isocitrate Dehydrogenase Gene Mutation in Chondrosarcoma
by: ZHAO Jingjing, ZHANG Zhihong, ZHEN Junping
Published: (2024-04-01)

Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias
by: Ugo Testa, et al.
Published: (2020-08-01)

Cytosolic Isocitrate Dehydrogenase from Arabidopsis thaliana Is Regulated by Glutathionylation
by: Adnan Khan Niazi, et al.
Published: (2019-01-01)

Diagnostic performance of clinical properties and conventional magnetic resonance imaging for determining the IDH1 mutation status in glioblastoma: a retrospective study
by: Qun Wang, et al.
Published: (2019-06-01)

Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma
by: Christine Jungk, et al.
Published: (2019-01-01)

Research Progress of Isocitrate Dehydrogenase Gene Mutation Therapy
by: LIN Meijia, et al.
Published: (2023-03-01)

Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations
by: Pasquale Persico, et al.
Published: (2022-02-01)

Wild-Type Isocitrate Dehydrogenase-Dependent Oxidative Decarboxylation and Reductive Carboxylation in Cancer and Their Clinical Significance
by: Qiwei He, et al.
Published: (2022-11-01)

Metabolic Rewiring in Adult-Type Diffuse Gliomas
by: Jong-Whi Park
Published: (2023-04-01)

Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy
by: Karen Schoedel, et al.
Published: (2024-01-01)

Identification of potential target genes for isocitrate dehydrogenase mutations in cholangiocarcinoma
by: WANG Di, LI Qing, TONG Wei-min, NIU Ya-mei
Published: (2020-04-01)

Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
by: Chi-Ming Chang, et al.
Published: (2023-05-01)

Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors
by: Santosh Sharma, et al.
Published: (2023-08-01)

Implications of Cellular Immaturity in Necrosis and Microvascularization in Glioblastomas IDH-Wild-Type
by: Cristian Ionut Orasanu, et al.
Published: (2022-12-01)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
by: Ali S. Haider, et al.
Published: (2023-04-01)

T2/FLAIR Abnormity Could be the Sign of Glioblastoma Dissemination
by: Mingxiao Li, et al.
Published: (2022-02-01)

Efficacy of Personalized Postoperative Epilepsy Management in Patients with Glioblastoma Utilizing IDH1 Gene Assessment
by: Meng GQ, et al.
Published: (2024-04-01)

(2<i>R</i>,3<i>S</i>)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia
by: Jeffrey R. Idle, et al.
Published: (2020-10-01)

Two Different Isocitrate Dehydrogenases from <i>Pseudomonas aeruginosa</i>: Enzymology and Coenzyme-Evolutionary Implications
by: Xuefei Chen, et al.
Published: (2023-10-01)

Beyond Imaging and Genetic Signature in Glioblastoma: Radiogenomic Holistic Approach in Neuro-Oncology
by: Lidia Gatto, et al.
Published: (2022-12-01)

Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI
by: Laiz Laura de Godoy, et al.
Published: (2023-09-01)

A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database
by: Amrit L. Pappula, et al.
Published: (2021-08-01)

Association of <i>TP53</i> Alteration with Tissue Specificity and Patient Outcome of <i>IDH1</i>-Mutant Glioma
by: Balazs Murnyak, et al.
Published: (2021-08-01)

Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma
by: Makoto Nakagawa, et al.
Published: (2022-06-01)

Upstaging and Downstaging in Gliomas—Clinical Implications for the Fifth Edition of the World Health Organization Classification of Tumors of the Central Nervous System
by: Oana Gabriela Trifănescu, et al.
Published: (2023-01-01)

Hypoxia and Microvascular Alterations Are Early Predictors of IDH-Mutated Anaplastic Glioma Recurrence
by: Andreas Stadlbauer, et al.
Published: (2021-04-01)

Conventional MRI-Derived Biomarkers of Adult-Type Diffuse Glioma Molecular Subtypes: A Comprehensive Review
by: Paola Feraco, et al.
Published: (2022-10-01)

The Association of Alpha-thalassemia X-Linked Intellectual Disability Mutation with Histopathological Grading in Isocitrate- Dehydrogenase-mutant Glioma
by: Alva Sinung Anindita, et al.
Published: (2023-12-01)

A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with <i>IDH1</i>-Mutated Solid Tumors
by: Mohammed Khurshed, et al.
Published: (2021-05-01)

Quantitative analysis using intraoperative contrast-enhanced ultrasound in adult-type diffuse gliomas with isocitrate dehydrogenase mutations: association between hemodynamics and molecular features
by: Xiandi Zhang, et al.
Published: (2023-10-01)